Tech Spotlight: Peptides for Modulating T-Cell Activity, for Treatment of Inflammation and Autoimmune Disease

A major concern in autoimmune diseases like type 1 diabetes (T1D), multiple sclerosis, rheumatoid arthritis, etc. is safely treating the destructive inflammation. During these diseases, persistent debilitating inflammation leads to tissue destruction and eventual loss of function. In T1D, for example, cells of the immune system (including T cells) migrate to the pancreas and attack the insulin producing beta islet cells. Inflammation is established in the islets, leading to loss of insulin production.

A University of Colorado research group lead by David Wagner has developed a novel method for modulating autoimmune inflammation by directly impacting the primary cells responsible for the destructive inflammation. This product is a small peptide that has been shown to prevent type I diabetes in the animal disease model; and to reverse hyperglycemia in new-onset mice. Extensive study based on size and composition of the peptide has indicated lead candidates for drug development; Dr. Wagner's work also enables monitoring of treat efficacy.

To read a non-confidential summary of this technology, including links to relevant patent and scientific documents, please click the image above. For more CU technologies available for licensing, please visit our Tech Explorer site.